Xintela publishes safety and efficacy results from knee osteoarthritis clinical study with XSTEM in scientific journal
The positive results from Xintela’s (XINT) clinical study (Phase I/IIa) on XSTEM for knee osteoarthritis have now been published in the peer-reviewed scientific journal Cartilage. The results show in addition to safety that the XSTEM treatment reduced knee pain, improved joint function and improved cartilage and bone tissue, supporting a disease-modifying effect of XSTEM. The […]
Xintela raises a convertible loan of SEK 30 million
Xintela has entered into an agreement to raise a convertible loan of SEK 30 million from the Company’s principal shareholder, Flerie Invest, to accelerate the development of XSTEM® for the treatment of osteoarthritis, to repay the previous loan from Fenja Capital II and to meet the Company’s general working capital requirements. Xintela AB (publ) (“Xintela” […]
Xintela AB Interim Report January – March 2026
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupFirst quarter 2026Income amounted to TSEK 443 (140).Loss before tax totalled TSEK 11,780 (loss: 10,661).Loss per share was SEK 0.02 (loss: 0.02). The Parent companyFirst quarter 2026Income amounted to TSEK 443 (140).Loss before tax totalled TSEK 10,704 (loss: 8,574). […]
Xintela granted patent in Japan for XSTEM® treatment of acute respiratory distress syndrome (ARDS)
Xintela (XINT) announces that the Japanese Patent Office (JPO) has granted a patent covering the company’s stem cell product XSTEM® for the treatment of acute respiratory distress syndrome (ARDS) and related disorders. The patent, JP 7821414, can be kept in force in Japan until 7 May 2041. Japan is the world’s third largest pharmaceutical market […]
Xintela AB publishes Annual Report 2025
Xintela AB (publ) announces that the company’s annual report for 2025 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela (XINT) is a publicly-traded clinical-stage biopharma company, […]
Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper
The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) has previously been published in the scientific journal Cartilage. The results show less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. The publication has now been awarded best basic science […]
Xintela AB Year-end Report 2025
Summary of the year-end reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2025Income amounted to TSEK 415 (1,090).Loss before tax totalled TSEK 17,343 (loss: 11,712).Loss per share was SEK 0.02 (loss: 0.02). Full year 2025Income amounted to TSEK 2,282 (4,215).Loss before tax totalled TSEK 50,158 (loss: 41,534).Loss per share […]
Xintelling No. 1 2026
Read Xintela´s newsletter in English here Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela (XINT) is a publicly-traded clinical-stage biopharma company, that develops cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela’s proprietary technology uses the stem cell marker integrin […]
Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers
Xintela (XINT) announces that the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers has been completed with the last follow-up visit for the last patient. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s Phase I/IIa clinical study in patients […]
Xintela AB Interim Report January – September 2025
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2025Income amounted to TSEK 855 (2,822).Loss before tax totalled TSEK 10,035 (loss: 8,049).Loss per share was SEK 0.01 (loss: 0.01). First nine month of 2025Income amounted to TSEK 1,867 (3,125).Loss before tax totalled TSEK 32,816 (loss: […]
